Literature DB >> 16236754

Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma.

K Tanimoto1, A Kaneko, S Suzuki, N Sekiguchi, D Maruyama, S W Kim, T Watanabe, Y Kobayashi, Y Kagami, A Maeshima, Y Matsuno, K Tobinai.   

Abstract

BACKGROUND: The majority of lymphomas in the ocular adnexa are low-grade B-cell lymphomas of mucosa-associated lymphoid tissue (MALT lymphoma). Although radiotherapy is the most frequently applied management, cataract and dry eye are problematic complications. PATIENTS AND METHODS: Between 1973 and 2003, the clinical features of 36 patients with ocular adnexal MALT lymphoma with no symptoms who were managed with no initial therapy after biopsy or surgical resection were retrospectively analyzed.
RESULTS: The median patient age was 63 years (range 22-84) and all patients had stage I disease, consisting of 31 unilateral cases and five bilateral cases. With a median follow-up of 7.1 years, 25 (69%) did not require treatment. The median time until the initiation of treatment in the remaining 11 patients (31%) was 4.8 years. Six patients (17%) died, and among them only two (6%) died due to progressive lymphoma. Seventeen patients (47%) progressed, but histologic transformation was recognized in only one (3%). The estimated overall survival rates of the 36 patients after 5, 10 and 15 years were 94%, 94% and 71%, respectively.
CONCLUSIONS: In selected patients with ocular adnexal MALT lymphoma, no initial therapy might be an acceptable approach, because 70% of patients remained untreated at a median of 8.6 years, and their survival was comparable to that of reports on immediate therapy.

Entities:  

Mesh:

Year:  2005        PMID: 16236754     DOI: 10.1093/annonc/mdj025

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  25 in total

1.  Orbital and ocular adnexal Mucosa-Associated Lymphoid Tissue (MALT) lymphomas: a single-center 10-year experience.

Authors:  M Smiljanic; R Milosevic; D Antic; B Andjelic; V Djurasinovic; M Todorovic; J Bila; A Bogdanovic; B Mihaljevic
Journal:  Med Oncol       Date:  2013-09-13       Impact factor: 3.064

2.  [Clarithromycin for monotherapy of B-cell MALT lymphoma?].

Authors:  C Auw-Hädrich; J Finke; A Serr; H Mittelviefhaus; C Bogdan; T Reinhard
Journal:  Ophthalmologe       Date:  2013-11       Impact factor: 1.059

3.  Treatment-associated outcomes of patients with primary ocular adnexal MALT lymphoma after accurate diagnosis.

Authors:  Yuya Masuda; Kazuto Takeuchi; Toshio Kodama; Tomoaki Fujisaki; Yoshitaka Imaizumi; Eiichi Otsuka; Shuji Ozaki; Shinji Hasebe; Yoshihiro Yakushijin
Journal:  Int J Clin Oncol       Date:  2019-06-06       Impact factor: 3.402

Review 4.  Ocular adnexal marginal zone lymphoma of mucosa-associated lymphoid tissue.

Authors:  Dimitrios Kalogeropoulos; Alexandra Papoudou-Bai; Panagiotis Kanavaros; Chris Kalogeropoulos
Journal:  Clin Exp Med       Date:  2017-09-22       Impact factor: 3.984

5.  Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patients.

Authors:  Soley Bayraktar; Ulas D Bayraktar; Alexandra Stefanovic; Izidore S Lossos
Journal:  Br J Haematol       Date:  2010-11-18       Impact factor: 6.998

6.  Primary Orbital Follicular Lymphoma: A Case Report and Review.

Authors:  G Lakshmi Prasad; Ajay Hegde; Girish Menon; Mary Mathew
Journal:  J Clin Diagn Res       Date:  2017-03-01

7.  [Orbital neoplasia. Part II: mesenchymal, leukemic, lymphoproliferative and bony tumors, metastasis].

Authors:  M P Schittkowski; N Fichter
Journal:  Ophthalmologe       Date:  2013-01       Impact factor: 1.059

Review 8.  The role of infectious agents in the etiology of ocular adnexal neoplasia.

Authors:  Varun Verma; Defen Shen; Pamela C Sieving; Chi-Chao Chan
Journal:  Surv Ophthalmol       Date:  2008 Jul-Aug       Impact factor: 6.048

Review 9.  Extranodal marginal zone lymphoma of the ocular adnexa.

Authors:  Alexandra Stefanovic; Izidore S Lossos
Journal:  Blood       Date:  2009-04-16       Impact factor: 22.113

10.  Treatment options for ocular adnexal lymphoma (OAL).

Authors:  Victoria Mary Lendrum Cohen
Journal:  Clin Ophthalmol       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.